BCR and diffuse large B-cell lymphoma: In the neoplastic setting of ABC DLBCL, the BCR and the NF-kB antiapoptotic pathway are constitutively active as a result of oncogenic mutations of CARD11 and/or CD79, with MYD88 mutations playing an external role in contributing at the same level [15].